

Draft Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
20 – 22 October 2015
EB Room, WHO, HQ, Geneva

Tuesday, 20 Oct 2015

Time	Session	Purpose of session, target outcomes and questions for SAGE	
8:30	Welcome – introduction of participants J. Abramson, Chair of SAGE		20 min.
8:50	Report from Director, IVB - Session 1 Global report including key updates and challenges from regions, J.-M. Okwo-Bele, WHO, 30 min. Discussion: 1h	FOR INFORMATION	1h 30 min.
10:20	Coffee/tea break	Break	30 min.
10:50	Ebola vaccines - Session 2 Introduction, F Were, SAGE member, 5 min. Summary of key data reviewed by SAGE WG <ul style="list-style-type: none"> a. Epidemiology and risk factors for EVD, B. Aylward and C. Dye, WHO, 15 min. b. Status of vaccine development , preliminary results from clinical trials, modelled projections of impact and deployment plans, V. Moorthy, AM. Henao Restrepo, M.P Preziosi, WHO, 35 min. c. Projections of impact of vaccination under different epidemiological scenarios , J Edmunds, LSHTM, 15 min. Blueprint for R&D during emergencies, M-P. Kieny, WHO, 10 min. Conclusions and draft recommendations from the WG, H. Rees, Co-chair Ebola WG, 10 min.	FOR DISCUSSION SAGE will be presented with the key data reviewed by the Working Group in formulating its draft conclusions and recommendations. The presentations will cover epidemiological issues, the status of vaccine development (including a summary of preliminary data from clinical trials), and projections on the impact of vaccination, using different vaccination strategies and in different epidemiological scenarios. In addition, SAGE will be presented with a proposed blueprint for R&D during public health emergencies. Finally, SAGE will be presented with the conclusions and draft recommendations for post-licensure vaccine use, for review	2h 30 min.

	Discussion: 1h		
13:20	Lunch	Break	1h 10 min.
14:30	Report from Gavi – Session 3 Report from the GAVI Alliance, S. Berkley, Gavi, 20 min. Discussion: 20 min.	FOR INFORMATION	40 min.
15:10	Global Polio Eradication Initiative - Session 4 Objective of the session; overview of Global Polio Eradication Initiative, H. Jafari, WHO, 15 min. Updates on preparation for OPV2 withdrawal (e.g. IPV introduction, operationalizing OPV2 withdrawal, bOPV licensures and containment), M. Zaffran, WHO, 30 min.	FOR INFORMATION AND DECISION <u>For decision</u> <ul style="list-style-type: none"> · Reaffirm the OPV2 withdrawal date of April 2016, after careful assessment of progress toward the following: <ul style="list-style-type: none"> · Elimination of all persistent cVDPV2 · Preparedness for OPV2 withdrawal · Endorse the specific switch dates in April 2016 and the framework for monitoring tOPV withdrawal <u>For information</u> <ul style="list-style-type: none"> · To update SAGE on: <ul style="list-style-type: none"> · the current status of the polio eradication program · the contingency planning for vaccine supply · the status of polio legacy planning 	3h
15:55	Coffee/tea break	Break	30 min.

16:25	Global Polio Eradication Initiative - Session 4 (Contd.) Report from SAGE WG, Y. AL-Mazrou, Chair of the Polio Working Group, 30 min. Discussion: 70 min. Updates on legacy planning, P. Rutter, WHO, 15 min. Discussion: 20 min.		
18:40	Cocktail		

Wednesday, 21 Oct 2015

09:00	<p>Measles and rubella vaccines - Session 5</p> <p>Update on global measles and rubella control and regional elimination, P. Strebel, WHO, 15 min.</p> <p>Refinements to the vaccination strategies for measles and rubella control and elimination (i.e., use of a supplemental dose of measles containing vaccine (MCV) among infants <9 months of age, determining the target age range for M and MR SIA), P. Figueroa, Member and previous Chair of the SAGE Working Group on measles and rubella vaccines, 30 min.</p> <p>Measles revaccination of HIV-infected children on anti-retroviral therapy, W. Moss, Member of the SAGE Working Group on measles and rubella vaccines, 15 min.</p> <p>Discussion: 60 min</p>	<p>FOR DISCUSSION AND DECISION</p> <p>For discussion</p> <ul style="list-style-type: none"> · To review the current status of global measles and rubella control and regional elimination · To review the plans for a Midterm Review of the Measles and Rubella Strategic plan · To review how existing data can be used to determine the target age range for M and MR SIAs <p>For decision</p> <ul style="list-style-type: none"> · Epidemiological settings in which a supplemental dose of MCV is recommended for infants aged <9 months · Measles revaccination of HIV-infected children on anti-retroviral therapy 	2h
11:00	Coffee/tea break	Break	30 min.
11:30	<p>Reports from other Advisory Committees on Immunization - Session 6</p> <p>Report of the Global Advisory Committee on Vaccine Safety (GACVS), M. Wharton, Chair of GACVS, 10 min.</p> <p>Discussion: 10 min.</p> <p>Report of the Product Development for Vaccines Advisory Committee (PDVAC), D. Kaslow, Chair of PDVAC, 10 min.</p> <p>Discussion: 10 min.</p> <p>Report of the Immunization Practices Advisory Committee (IPAC), C. Morgan, Chair of IPAC. 10 min.</p> <p>Discussion: 10 min.</p> <p>Report of the Immunization and vaccines related implementation research advisory committee (IVIR-AC), G. Kang, Member of IVIR-AC, 10 min.</p> <p>Discussion: 10 min.</p> <p>Report of the Expert Committee on Biological Standardization (ECBS), E. Griffiths, Chair of ECBS, 10 min.</p> <p>Discussion: 10 min.</p>	FOR INFORMATION	1h 40 min.

13:10	Lunch	Break	1h
14:10	<p>Malaria Vaccine Jointly Co-Chaired Malaria Policy Advisory Committee (MPAC)/SAGE - Session 7</p> <p>Opening comments to session. F. Binka, Acting Chair of MPAC, and J. Abramson, Chair of SAGE, 10 min.</p> <p>Malaria disease burden, epidemiology, status of malaria control and surveillance, and the need for new interventions. K. Marsh, African Academy of Sciences, 20 min.</p> <p>Review of RTS,S clinical trial results. P. Smith, Chair of JTEG, 30 min. Discussion: 30 min.</p>	<p>FOR DECISION</p> <p>Present SAGE and MPAC with the report of the Joint Technical Expert Group (JTEG) on the RTS,S malaria vaccine and request SAGE/MPAC's consideration of the proposed recommendations.</p> <p>SAGE/MPAC recommendations on vaccine use will then be used to write the first WHO position paper on the use of a malaria vaccine.</p>	3h 30 min
15:40	Coffee/tea break		30 min.
16:10	<p>Malaria Vaccine Jointly Co-Chaired Malaria Policy Advisory Committee (MPAC)/SAGE meeting- Session 7 (Contd.)</p> <p>JTEG assessment and proposed recommendations. P. Smith, Chair of JTEG, 20 min.</p> <p>Discussion: 80 min.</p> <p>Wrap-up of discussion and agreed SAGE/MPAC recommendations. F. Binka, Acting Chair of MPAC, 20 min.</p>		
18:10	End of day		

Thursday, 22 Oct 2015

08:30	<p>Global Vaccine Action Plan: progress report - Session 8</p> <p>The GVAP Secretariat Report 2015: Update on process, new indicators, actions taken by the secretariat in response to previous reports, T. Cherian (on behalf of the Secretariat of the Decade of Vaccines Working Group), WHO, 15 min.</p> <p>Summary of GVAP implementation progress review and recommendations for corrective actions, N. Arora, Chair of the SAGE Decade of Vaccines Working Group, 30 min.</p> <p>Discussion: 1h 45 min</p>	<p>FOR DISCUSSION AND DECISION</p> <p>SAGE will be expected to produce an independent annual report on progress with the Decade of Vaccines Global Vaccine Action Plan.</p> <p>Specially, SAGE will be asked to:</p> <ul style="list-style-type: none"> • Review the DoV WG "Assessment report on DoV progress 2015" based on the "GVAP Secretariat report 2015" and some Independent stakeholder submissions. • Make recommendations on any necessary changes to the formulation of the indicators, operational definitions and/or the processes for data collection. • Identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed. • Provide recommendations and corrective actions for Members States, regions, partners, donor agencies "SAGE Assessment report on the Decade of Vaccines progress" which will be the basis of the "progress report" for the WHO Executive Board and World Health Assembly. 	2h 30 min
11:00	Coffee/tea break	Break	30 min.
11:30	<p>Report on activities from international immunization partners – Session 9</p> <p>Presentation by UNICEF, H. Deehan, UNICEF, 20min.</p> <p>Discussion: 20min</p> <p>Presentation by MSF, A. Juan-Giner, Médecins Sans Frontières (MSF), 20min.</p> <p>Discussion: 20min</p>	<p>FOR INFORMATION</p> <p>This will be the launch of the series of presentations to be held at future SAGE meetings on the immunization-related activities of partners working in the field of immunization.</p>	1h 20 min.
12:50	Closing		20 min.
13:10	End of meeting		